Hepatoprotective Effects of Sericin on Aging-induced Liver Damage in Mice

Aging is a physiological process in which there is a progressive decline of function in multiple organs such as the liver. The development of natural therapies, such as sericin, for delaying age-associated diseases is of major interest in this regard. Twenty-seven mice were divided into three groups of nine, including young control group (8 weeks, received normal saline), aged control group (24 months, received normal saline), and sericin-treated aged mice (24 months, received sericin at dose 100 mg/kg/day) via oral administration for 14 days. The liver enzymes in serum and oxidative stress markers in liver tissue were evaluated using spectrophotometric/ELISA methods. Apoptotic proteins, pro-inflammatory cytokines, COX2, JNK, and P-38 levels were assessed by western blot analysis. β-galactosidase expression was determined by a qRT-PCR method. The findings showed that 100 mg/kg of sericin reduced liver enzymes in aged mice. Antioxidant capacity in treated aged mice showed an improvement in all indexes in the liver tissue. Also, sericin administration declined pro-inflammatory markers to varying degrees in aged-treated mice. Sericin also increased the expression level of Bcl-2 and decreased the expression level of Bax and cleaved caspase-3.In addition, treatment with sericin suppressed protein expression of p-JNK and p-JNK/JNK. Collectively, these findings would infer that sericin administration may have a hepatoprotective effect in aging-induced liver damage in mice.